Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
- Overview
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2021
published in
- JAMA Journal
has subject area
- Aged
- Aged, 80 and over
- Alzheimer Disease
- Antibodies, Monoclonal, Humanized
- Clinical Trials, Phase III as Topic
- Cognitive Dysfunction
- Contraindications, Drug
- Drug Approval
- Early Termination of Clinical Trials
- Female
- Humans
- Insurance Claim Review
- Male
- Medicare
- Middle Aged
- Patient Selection
- United States
- United States Food and Drug Administration